JP2021526858A5 - - Google Patents
Info
- Publication number
- JP2021526858A5 JP2021526858A5 JP2021518052A JP2021518052A JP2021526858A5 JP 2021526858 A5 JP2021526858 A5 JP 2021526858A5 JP 2021518052 A JP2021518052 A JP 2021518052A JP 2021518052 A JP2021518052 A JP 2021518052A JP 2021526858 A5 JP2021526858 A5 JP 2021526858A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- composition according
- binding polypeptide
- polypeptide
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682271P | 2018-06-08 | 2018-06-08 | |
| US62/682,271 | 2018-06-08 | ||
| PCT/US2019/036021 WO2019236982A1 (en) | 2018-06-08 | 2019-06-07 | Rna-targeting fusion protein compositions and methods for use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021526858A JP2021526858A (ja) | 2021-10-11 |
| JP2021526858A5 true JP2021526858A5 (cg-RX-API-DMAC7.html) | 2022-06-15 |
Family
ID=68769584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518052A Pending JP2021526858A (ja) | 2018-06-08 | 2019-06-07 | Rna標的化融合タンパク質組成物および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200071718A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3802812A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021526858A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210058806A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112930395A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019280990A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3102779A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202012004SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019236982A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011160052A2 (en) | 2010-06-18 | 2011-12-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for sequence specific rna endonucleases |
| EP3765094A4 (en) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY |
| CN113544267B (zh) | 2019-01-14 | 2025-04-18 | 罗切斯特大学 | 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化 |
| WO2021016453A1 (en) * | 2019-07-23 | 2021-01-28 | University Of Rochester | Targeted rna cleavage with crispr-cas |
| US11572565B2 (en) | 2020-07-21 | 2023-02-07 | Trustees Of Boston University | Inducible control of gene expression |
| CN112126645B (zh) * | 2020-09-11 | 2021-06-01 | 广州吉赛生物科技股份有限公司 | 一种环形rna敲低方法及其应用 |
| CN112430597A (zh) * | 2020-11-24 | 2021-03-02 | 深圳市瑞吉生物科技有限公司 | 一种使目的基因沉默的CasRx制剂及其应用 |
| US20240000972A1 (en) * | 2020-12-01 | 2024-01-04 | Locanabio, Inc. | Rna-targeting compositions and methods for treating cag repeat diseases |
| CN117320741A (zh) * | 2020-12-01 | 2023-12-29 | 洛卡纳生物股份有限公司 | 用于治疗cag重复疾病的靶向rna的组合物和方法 |
| WO2022119979A1 (en) * | 2020-12-01 | 2022-06-09 | Locanabio, Inc. | Rna-targeting compositions and methods for treating myotonic dystrophy type 1 |
| GB202105455D0 (en) | 2021-04-16 | 2021-06-02 | Ucl Business Ltd | Composition |
| US20250320258A1 (en) * | 2021-06-02 | 2025-10-16 | The Regents Of The University Of California | Rna recognition complex and uses thereof |
| JP2025500531A (ja) * | 2021-12-27 | 2025-01-09 | グラセル バイオテクノロジーズ(シャンハイ)カンパニー,リミテッド | 細胞改変のための系及び方法 |
| CN114835776B (zh) * | 2022-04-08 | 2023-09-01 | 陕西师范大学 | 一种靶向Smad4/PELO相互作用的抵抗肿瘤转移小分子多肽及应用 |
| CN116949011A (zh) * | 2022-04-26 | 2023-10-27 | 中国科学院动物研究所 | 经分离的Cas13蛋白、基于它的基因编辑系统及其用途 |
| WO2024092230A2 (en) * | 2022-10-28 | 2024-05-02 | The Regents Of The University Of California | Recombinant enhanced antiviral restrictors |
| CN115820603B (zh) * | 2022-11-15 | 2024-07-05 | 吉林大学 | 一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2182063A3 (en) * | 2003-09-18 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Modulation of EIF4E expression |
| US20110002981A1 (en) * | 2006-12-20 | 2011-01-06 | Kolattukudy Pappachan E | MCPIP Protection Against Cardiac Dysfunction |
| WO2011160052A2 (en) * | 2010-06-18 | 2011-12-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for sequence specific rna endonucleases |
| US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
| ES2751126T3 (es) | 2011-10-21 | 2020-03-30 | Univ Kyushu Nat Univ Corp | Método de diseño para proteína de unión a ARN usando motivo de PPR, y uso del mismo |
| JP6793547B2 (ja) * | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物 |
| WO2015138855A1 (en) * | 2014-03-14 | 2015-09-17 | The Regents Of The University Of California | Vectors and methods for fungal genome engineering by crispr-cas9 |
| US10330674B2 (en) | 2015-01-13 | 2019-06-25 | Massachusetts Institute Of Technology | Pumilio domain-based modular protein architecture for RNA binding |
| US10392607B2 (en) | 2015-06-03 | 2019-08-27 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| AU2016359629B2 (en) * | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| CN109152808A (zh) * | 2016-04-29 | 2019-01-04 | 生物辐射实验室股份有限公司 | 用于核酸序列的特异性靶向的二聚蛋白质 |
| US12180499B2 (en) | 2016-10-31 | 2024-12-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for impeding transcription of expanded microsatellite repeats |
| CN110959039B (zh) | 2017-03-15 | 2025-03-14 | 博德研究所 | 新型cas13b直向同源物crispr酶和系统 |
| KR102357045B1 (ko) | 2017-03-31 | 2022-01-28 | 뉴로디아그노스틱스 엘엘씨 | 알츠하이머 질환에 대한 림프구-기반 형태계측 시험 |
| US10392616B2 (en) | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| US10476825B2 (en) | 2017-08-22 | 2019-11-12 | Salk Institue for Biological Studies | RNA targeting methods and compositions |
| JP2021526860A (ja) | 2018-06-08 | 2021-10-11 | ロックアネイビオ, インコーポレイテッド | 適応免疫をモジュレートするための組成物および方法 |
| EP3841116A4 (en) * | 2018-08-24 | 2022-05-25 | Locanabio, Inc. | FASL IMMUNOMODULATING GENE THERAPY COMPOSITIONS AND METHODS OF USE |
-
2019
- 2019-06-07 CN CN201980050249.4A patent/CN112930395A/zh active Pending
- 2019-06-07 EP EP19815645.7A patent/EP3802812A4/en not_active Withdrawn
- 2019-06-07 SG SG11202012004SA patent/SG11202012004SA/en unknown
- 2019-06-07 AU AU2019280990A patent/AU2019280990A1/en not_active Abandoned
- 2019-06-07 CA CA3102779A patent/CA3102779A1/en active Pending
- 2019-06-07 US US16/434,689 patent/US20200071718A1/en not_active Abandoned
- 2019-06-07 KR KR1020217000538A patent/KR20210058806A/ko not_active Abandoned
- 2019-06-07 WO PCT/US2019/036021 patent/WO2019236982A1/en not_active Ceased
- 2019-06-07 JP JP2021518052A patent/JP2021526858A/ja active Pending
- 2019-12-20 US US16/723,079 patent/US10822617B2/en not_active Expired - Fee Related
-
2020
- 2020-08-24 US US17/001,318 patent/US20210047654A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7698828B2 (ja) | Rnaを編集する方法および組成物 | |
| JP7672445B2 (ja) | CasZ組成物及び使用方法 | |
| JP7252328B2 (ja) | Rnaを編集する方法および組成物 | |
| JP2025026840A5 (cg-RX-API-DMAC7.html) | ||
| CN111094561B (zh) | 靶特异性crispr变体 | |
| AU2025263805A1 (en) | Novel crispr enzymes and systems | |
| US11111506B2 (en) | Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides | |
| JP2026083211A (ja) | 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法 | |
| CN111757889A (zh) | 新型CRISPR/Cas12f酶和系统 | |
| JP2023027277A (ja) | Rna誘導型核酸修飾酵素及びその使用方法 | |
| JP2022519507A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518139A5 (cg-RX-API-DMAC7.html) | ||
| CN109072235B (zh) | 通过核递送crispr/cas9追踪并操纵细胞rna | |
| CN113811607A (zh) | CRISPR-Cas效应子多肽和其使用方法 | |
| JP2021526860A5 (cg-RX-API-DMAC7.html) | ||
| JP2020022459A5 (cg-RX-API-DMAC7.html) | ||
| KR20160089530A (ko) | Hbv 및 바이러스 질병 및 질환을 위한 crisprcas 시스템 및 조성물의 전달,용도 및 치료적 적용 | |
| CN114040971A (zh) | CRISPR-Cas效应子多肽及其使用方法 | |
| US20260022359A1 (en) | Compositions and methods for nucleic acid modifications | |
| JP2021533812A5 (cg-RX-API-DMAC7.html) | ||
| KR102626503B1 (ko) | 뉴클레오타이드 표적 인식을 이용한 표적 서열 특이적 개변 기술 | |
| KR20240164823A (ko) | 게놈 편집의 조성물및 방법 | |
| JP2021536250A5 (cg-RX-API-DMAC7.html) | ||
| JP2020533411A5 (cg-RX-API-DMAC7.html) | ||
| CN107151677A (zh) | 基于CRISPR/Cas9多基因敲除低转染效率细胞系的新方法 |